ImmuniQ has developed a method for quantifing the actual and functional tumor response to immunotherapy drugs. The company’s immune checkpoint artificial reporter (IcAR) technology is able to quantify binding and shows the actual surface activity of the patient’s cancer cells, enabling more effective treatment for each patient.